...
首页> 外文期刊>Cytotherapy >Selection of CD271+ cells and human AB serum allows a Large expansion of mesenchymal stromal cells from human bone marrow
【24h】

Selection of CD271+ cells and human AB serum allows a Large expansion of mesenchymal stromal cells from human bone marrow

机译:选择CD271 +细胞和人AB血清可使人骨髓中的间充质基质细胞大量扩增

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background Mesenchymal stromal cells (MSC) are promising candidates for cell therapy and tissue engineering and may be used to treat acute graft-versus-host disease (GvHD). However, major obstacles for their clinical use are the required cell dose and the biosafety and potential immunogenicity of fetal bovine serum (FBS), which is a crucial supplement of all media currently used for the culture of MSC. Methods In this study MSC were successfully expanded after selection of CD271 cells from human bone marrow (BM) mononuclear cells in medium supplemented with 10% pooled allogeneic human serum. Results We isolated MSC from 10 healthy donor BM by plastic adherence and immunomagnetic selection of the CD271+ fraction and expanded MSC in medium supplemented with pooled human allogeneic serum and animal serum. We isolated a homogeneous multipotent population by CD271+ selection with a proliferation rate that was higher than MSC isolated by plastic adherence, 6.81.57 compared with 2.071.40 logs. Similar to cells generated in animal serum medium, MSC from allogeneic human serum were positive for mesenchymal markers and negative for hematopoietic markers; moreover they expressed embryonic stem cell genes. A normal karyotype and differentiation capacity into adipogenic, osteogenic and chondrogenic lineages and neurosphere-like structures were preserved throughout long-term culture. Discussion Expansion of MSC is both feasible and large with a CD271-selected population in medium supplemented with 10% pooled allogeneic human serum, without loss of multipotent differentiation capacity or karyotype alterations.
机译:背景间充质基质细胞(MSC)是细胞治疗和组织工程的有希望的候选者,可用于治疗急性移植物抗宿主病(GvHD)。但是,其临床应用的主要障碍是所需的细胞剂量以及胎牛血清(FBS)的生物安全性和潜在的免疫原性,这是目前用于MSC培养的所有培养基的重要补充。方法在本研究中,在补充了10%异体混合人血清的培养基中,从人骨髓(BM)单核细胞中选择了CD271细胞后,成功扩增了MSC。结果我们通过塑性粘附和CD271 +组分的免疫磁选从10个健康供体BM中分离了MSC,并在补充了人类同种异体血清和动物血清的培养基中扩增了MSC。我们通过CD271 +选择分离出一个同质多能种群,其增殖速率高于通过塑料粘附分离的MSC 6.81.57,而原本为2.071.40 log。与动物血清培养基中产生的细胞相似,同种异体人类血清中的MSC的间充质标记阳性,而造血标记阴性。此外,他们表达了胚胎干细胞基因。在整个长期培养过程中,都保持了正常的核型和向脂肪形成,成骨和成软骨谱系以及神经球样结构的分化能力。讨论MSC的扩增既可行,又可行,并且可以在补充了10%的同种异体人类血清的培养基中添加CD271选择的种群,而不会丧失多能分化能力或核型改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号